ATXI - Avenue Therapeutics Inc
(NaN%)
We couldn't determine Recommendation based on the data we have.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Avenue Therapeutics Inc (ATXI) - http://www.avenuetx.com/
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.Exchange - NASDAQ
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO -
Employees - 11
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.